APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Vaccine

A vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and keep a record of it so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters. Vaccines can be prophylactic (example: to prevent or ameliorate the effects of a future infection by any natural or "wild" pathogen), or therapeutic (e.g., vaccines against cancer are being investigated).

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

A vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and keep a record of it so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters. Vaccines can be prophylactic (example: to prevent or ameliorate the effects of a future infection by any natural or "wild" pathogen), or therapeutic (e.g., vaccines against cancer are being investigated).

Selected research

Market Analysis & Forecast

Global Vaccine Market Analysis and Forecast 2026-2032

Report ID 17404476022 January 2026219 pages

Choose your research edition.

Industry ResearchVaccine Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Vaccine Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vaccine Market Outlook and Growth Opportunities 2026217 pages · $4,250 USDMarket Analysis & ForecastGlobal Vaccine Market Analysis and Forecast 2026-2032219 pages · $4,950 USD

Market perspective

A vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and keep a record of it so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters. Vaccines can be prophylactic (example: to prevent or ameliorate the effects of a future infection by any natural or "wild" pathogen), or therapeutic (e.g., vaccines against cancer are being investigated).

The global Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Europe market for Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Asia-Pacific market for Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Vaccine include AstraZeneca, BioNTech, Boehringer-Ingelheim, CCBIO, CSL, CureVac, Elanco, GSK and Hulan Bio, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Vaccine, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Vaccine, also provides the revenue of main regions and countries. Of the upcoming market potential for Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Vaccine revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Vaccine revenue, projected growth trends, production technology, application and end-user industry.

Vaccine Segment by Company

AstraZeneca

BioNTech

Boehringer-Ingelheim

CCBIO

CSL

CureVac

Elanco

GSK

Hulan Bio

Indian Immunologicals

Merck

Minhai Biotechnology

Mitsubishi Tanabe Pharma

Moderna Therapeutics

Mylan

Plumbline Life Sciences

Sanofi

Translate Bio

Walvax Biotechnology

Wuhan Institute of Biological Products

Zoties

Vaccine Segment by Type

Varicella Vaccine

Influenza Vaccine

Polio Vaccine

Hepatitis A Vaccine

Rabies Vaccine

BCG Vaccine

Hepatitis B

Pertussis, Diphtheria, Tetanus

Pneumococcal

Others

Vaccine Segment by Application

For Adult

For Child

Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Vaccine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Vaccine company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Vaccine revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Varicella Vaccine Major Player Table 3. Influenza Vaccine Major Player Table 4. Polio Vaccine Major Player Table 5. Hepatitis A Vaccine Major Player Table 6. Rabies Vaccine Major Player Table 7. BCG Vaccine Major Player Table 8. Hepatitis B Major Player Table 9. Pertussis, Diphtheria, Tetanus Major Player Table 10. Pneumococcal Major Player Table 11. Others Major Player Table 12. Global Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 13. For Adult Major Player Table 14. For Child Major Player Table 15. Vaccine Industry Trends Table 16. Vaccine Industry Drivers Table 17. Vaccine Industry Opportunities and Challenges Table 18. Vaccine Industry Restraints Table 19. Global Vaccine Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 20. Global Vaccine Market Size by Region (2021-2026) & (US$ Million) Table 21. Global Vaccine Market Share by Region (2021-2026) Table 22. Global Vaccine Market Size by Region (2027-2032) & (US$ Million) Table 23. Global Vaccine Market Share by Region (2027-2032) Table 24. Global Vaccine Revenue by Players (US$ Million) & (2021-2026) Table 25. Global Vaccine Revenue Market Share by Players (2021-2026) Table 26. Global Vaccine Key Players Ranking, 2024 VS 2025 VS 2026 Table 27. Global Vaccine Key Players Headquarters & Area Served Table 28. Global Vaccine Players, Product Type & Application Table 29. Global Vaccine Players Establishment Date Table 30. Global Players Market Concentration Ratio (CR5 and HHI) Table 31. Global Vaccine by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 32. Global Vaccine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 34. Global Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 35. Global Vaccine Revenue Market Share by Type (2021-2026) Table 36. Global Vaccine Revenue Market Share by Type (2027-2032) Table 37. Global Vaccine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 39. Global Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 40. Global Vaccine Revenue Market Share by Application (2021-2026) Table 41. Global Vaccine Revenue Market Share by Application (2027-2032) Table 42. AstraZeneca Company Information Table 43. AstraZeneca Business Overview Table 44. AstraZeneca Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. AstraZeneca Vaccine Product Portfolio Table 46. AstraZeneca Recent Development Table 47. BioNTech Company Information Table 48. BioNTech Business Overview Table 49. BioNTech Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. BioNTech Vaccine Product Portfolio Table 51. BioNTech Recent Development Table 52. Boehringer-Ingelheim Company Information Table 53. Boehringer-Ingelheim Business Overview Table 54. Boehringer-Ingelheim Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Boehringer-Ingelheim Vaccine Product Portfolio Table 56. Boehringer-Ingelheim Recent Development Table 57. CCBIO Company Information Table 58. CCBIO Business Overview Table 59. CCBIO Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. CCBIO Vaccine Product Portfolio Table 61. CCBIO Recent Development Table 62. CSL Company Information Table 63. CSL Business Overview Table 64. CSL Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. CSL Vaccine Product Portfolio Table 66. CSL Recent Development Table 67. CureVac Company Information Table 68. CureVac Business Overview Table 69. CureVac Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. CureVac Vaccine Product Portfolio Table 71. CureVac Recent Development Table 72. Elanco Company Information Table 73. Elanco Business Overview Table 74. Elanco Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Elanco Vaccine Product Portfolio Table 76. Elanco Recent Development Table 77. GSK Company Information Table 78. GSK Business Overview Table 79. GSK Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. GSK Vaccine Product Portfolio Table 81. GSK Recent Development Table 82. Hulan Bio Company Information Table 83. Hulan Bio Business Overview Table 84. Hulan Bio Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Hulan Bio Vaccine Product Portfolio Table 86. Hulan Bio Recent Development Table 87. Indian Immunologicals Company Information Table 88. Indian Immunologicals Business Overview Table 89. Indian Immunologicals Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 90. Indian Immunologicals Vaccine Product Portfolio Table 91. Indian Immunologicals Recent Development Table 92. Merck Company Information Table 93. Merck Business Overview Table 94. Merck Vaccine Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 95. Merck Vaccine Product Portfolio Table 96. Merck Recent Development Table 97. Minhai Biotechnology Company Information Table 98. Minhai Biotechnology Business Overview Table 99. Minhai Biotechnology Vaccine Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 100. Minhai Biotechnology Vaccine Product Portfolio Table 101. Minhai Biotechnology Recent Development Table 102. Mitsubishi Tanabe Pharma Company Information Table 103. Mitsubishi Tanabe Pharma Business Overview Table 104. Mitsubishi Tanabe Pharma Vaccine Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 105. Mitsubishi Tanabe Pharma Vaccine Product Portfolio Table 106. Mitsubishi Tanabe Pharma Recent Development Table 107. Moderna Therapeutics Company Information Table 108. Moderna Therapeutics Business Overview Table 109. Moderna Therapeutics Vaccine Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 110. Moderna Therapeutics Vaccine Product Portfolio Table 111. Moderna Therapeutics Recent Development Table 112. Mylan Company Information Table 113. Mylan Business Overview Table 114. Mylan Vaccine Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 115. Mylan Vaccine Product Portfolio Table 116. Mylan Recent Development Table 117. Plumbline Life Sciences Company Information Table 118. Plumbline Life Sciences Business Overview Table 119. Plumbline Life Sciences Vaccine Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 120. Plumbline Life Sciences Vaccine Product Portfolio Table 121. Plumbline Life Sciences Recent Development Table 122. Sanofi Company Information Table 123. Sanofi Business Overview Table 124. Sanofi Vaccine Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 125. Sanofi Vaccine Product Portfolio Table 126. Sanofi Recent Development Table 127. Translate Bio Company Information Table 128. Translate Bio Business Overview Table 129. Translate Bio Vaccine Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 130. Translate Bio Vaccine Product Portfolio Table 131. Translate Bio Recent Development Table 132. Walvax Biotechnology Company Information Table 133. Walvax Biotechnology Business Overview Table 134. Walvax Biotechnology Vaccine Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 135. Walvax Biotechnology Vaccine Product Portfolio Table 136. Walvax Biotechnology Recent Development Table 137. Wuhan Institute of Biological Products Company Information Table 138. Wuhan Institute of Biological Products Business Overview Table 139. Wuhan Institute of Biological Products Vaccine Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 140. Wuhan Institute of Biological Products Vaccine Product Portfolio Table 141. Wuhan Institute of Biological Products Recent Development Table 142. Zoties Company Information Table 143. Zoties Business Overview Table 144. Zoties Vaccine Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 145. Zoties Vaccine Product Portfolio Table 146. Zoties Recent Development Table 147. North America Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 148. North America Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 149. North America Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 150. North America Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 151. North America Vaccine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 152. North America Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 153. North America Vaccine Revenue by Country (US$ Million) & (2027-2032) Table 154. Europe Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 155. Europe Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 156. Europe Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 157. Europe Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 158. Europe Vaccine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 159. Europe Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 160. Europe Vaccine Revenue by Country (US$ Million) & (2027-2032) Table 161. China Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 162. China Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 163. China Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 164. China Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 165. Asia Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 166. Asia Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 167. Asia Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 168. Asia Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 169. Asia Vaccine Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 170. Asia Vaccine Revenue by Region (US$ Million) & (2021-2026) Table 171. Asia Vaccine Revenue by Region (US$ Million) & (2027-2032) Table 172. SAMEA Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 173. SAMEA Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 174. SAMEA Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 175. SAMEA Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 176. SAMEA Vaccine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 177. SAMEA Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 178. SAMEA Vaccine Revenue by Country (US$ Million) & (2027-2032) Table 179. Research Programs/Design for This Report Table 180. Authors List of This Report Table 181. Secondary Sources Table 182. Primary Sources List of Figures Figure 1. Vaccine Image Figure 2. Global Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 4. Varicella Vaccine Image Figure 5. Influenza Vaccine Image Figure 6. Polio Vaccine Image Figure 7. Hepatitis A Vaccine Image Figure 8. Rabies Vaccine Image Figure 9. BCG Vaccine Image Figure 10. Hepatitis B Image Figure 11. Pertussis, Diphtheria, Tetanus Image Figure 12. Pneumococcal Image Figure 13. Others Image Figure 14. Global Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 16. For Adult Image Figure 17. For Child Image Figure 18. Global Vaccine Market Size (US$ Million) & (2021-2032) Figure 19. Global Vaccine Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 20. Global Vaccine Market Share by Region: 2021 VS 2025 VS 2032 Figure 21. Global Vaccine Players Revenue Share Top 10 and Top 5 in 2025 Figure 22. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Vaccine Revenue Market Share by Type (2021-2032) Figure 26. Global Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Vaccine Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 28. Global Vaccine Revenue Market Share by Application (2021-2032) Figure 29. North America Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. North America Vaccine Revenue Share by Type (2021-2032) Figure 31. North America Vaccine Revenue Share by Application (2021-2032) Figure 32. North America Vaccine Revenue Share by Country (2021-2032) Figure 33. United States Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Canada Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Mexico Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Europe Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 37. Europe Vaccine Revenue Share by Type (2021-2032) Figure 38. Europe Vaccine Revenue Share by Application (2021-2032) Figure 39. Europe Vaccine Revenue Share by Country (2021-2032) Figure 40. Germany Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. France Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. U.K. Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Italy Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Spain Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Russia Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. Netherlands Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 47. Nordic Countries Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. China Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. China Vaccine Revenue Share by Type (2021-2032) Figure 50. China Vaccine Revenue Share by Application (2021-2032) Figure 51. Asia Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 52. Asia Vaccine Revenue Share by Type (2021-2032) Figure 53. Asia Vaccine Revenue Share by Application (2021-2032) Figure 54. Asia Vaccine Revenue Share by Region (2021-2032) Figure 55. Japan Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. South Korea Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. India Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Australia Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Taiwan Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Southeast Asia Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. SAMEA Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 62. SAMEA Vaccine Revenue Share by Type (2021-2032) Figure 63. SAMEA Vaccine Revenue Share by Application (2021-2032) Figure 64. SAMEA Vaccine Revenue Share by Country (2021-2032) Figure 65. Brazil Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Argentina Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Chile Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Colombia Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Peru Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Saudi Arabia Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Israel Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. UAE Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Turkey Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Iran Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 75. Egypt Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • Varicella Vaccine
  • Influenza Vaccine
  • Polio Vaccine
  • Hepatitis A Vaccine
  • Rabies Vaccine
  • BCG Vaccine
  • Hepatitis B
  • Pertussis, Diphtheria, Tetanus
  • Pneumococcal
  • Others
Applications
  • For Adult
  • For Child
Companies covered
  • AstraZeneca
  • BioNTech
  • Boehringer-Ingelheim
  • CCBIO
  • CSL
  • CureVac
  • Elanco
  • GSK
  • Hulan Bio
  • Indian Immunologicals
  • Merck
  • Minhai Biotechnology
  • Mitsubishi Tanabe Pharma
  • Moderna Therapeutics
  • Mylan
  • Plumbline Life Sciences
  • Sanofi
  • Translate Bio
  • Walvax Biotechnology
  • Wuhan Institute of Biological Products
  • Zoties

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Vaccine Market by Type
  3. 1.2.1 Global Vaccine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Varicella Vaccine
  5. 1.2.3 Influenza Vaccine
  6. 1.2.4 Polio Vaccine
  7. 1.2.5 Hepatitis A Vaccine
  8. 1.2.6 Rabies Vaccine
  9. 1.2.7 BCG Vaccine
  10. 1.2.8 Hepatitis B
  11. 1.2.9 Pertussis, Diphtheria, Tetanus
  12. 1.2.10 Pneumococcal
  13. 1.2.11 Others
  14. 1.3 Vaccine Market by Application
  15. 1.3.1 Global Vaccine Market Size by Application, 2021 VS 2025 VS 2032
  16. 1.3.2 For Adult
  17. 1.3.3 For Child
  18. 1.4 Assumptions and Limitations
  19. 1.5 Study Goals and Objectives
2 Vaccine Market Dynamics
  1. 2.1 Vaccine Industry Trends
  2. 2.2 Vaccine Industry Drivers
  3. 2.3 Vaccine Industry Opportunities and Challenges
  4. 2.4 Vaccine Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Vaccine Market Perspective (2021-2032)
  2. 3.2 Global Vaccine Growth Trends by Region
  3. 3.2.1 Global Vaccine Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Vaccine Market Size by Region (2021-2026)
  5. 3.2.3 Global Vaccine Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Vaccine Revenue by Players
  2. 4.1.1 Global Vaccine Revenue by Players (2021-2026)
  3. 4.1.2 Global Vaccine Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Vaccine Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Vaccine Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Vaccine Key Players Headquarters & Area Served
  7. 4.4 Global Vaccine Players, Product Type & Application
  8. 4.5 Global Vaccine Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Vaccine Market CR5 and HHI
  11. 4.6.3 2025 Vaccine Tier 1, Tier 2, and Tier 3
5 Vaccine Market Size by Type
  1. 5.1 Global Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Vaccine Revenue by Type (2021-2032)
  3. 5.3 Global Vaccine Revenue Market Share by Type (2021-2032)
6 Vaccine Market Size by Application
  1. 6.1 Global Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Vaccine Revenue by Application (2021-2032)
  3. 6.3 Global Vaccine Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 AstraZeneca
  2. 7.1.1 AstraZeneca Company Information
  3. 7.1.2 AstraZeneca Business Overview
  4. 7.1.3 AstraZeneca Vaccine Revenue and Gross Margin (2021-2026)
  5. 7.1.4 AstraZeneca Vaccine Product Portfolio
  6. 7.1.5 AstraZeneca Recent Developments
  7. 7.2 BioNTech
  8. 7.2.1 BioNTech Company Information
  9. 7.2.2 BioNTech Business Overview
  10. 7.2.3 BioNTech Vaccine Revenue and Gross Margin (2021-2026)
  11. 7.2.4 BioNTech Vaccine Product Portfolio
  12. 7.2.5 BioNTech Recent Developments
  13. 7.3 Boehringer-Ingelheim
  14. 7.3.1 Boehringer-Ingelheim Company Information
  15. 7.3.2 Boehringer-Ingelheim Business Overview
  16. 7.3.3 Boehringer-Ingelheim Vaccine Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Boehringer-Ingelheim Vaccine Product Portfolio
  18. 7.3.5 Boehringer-Ingelheim Recent Developments
  19. 7.4 CCBIO
  20. 7.4.1 CCBIO Company Information
  21. 7.4.2 CCBIO Business Overview
  22. 7.4.3 CCBIO Vaccine Revenue and Gross Margin (2021-2026)
  23. 7.4.4 CCBIO Vaccine Product Portfolio
  24. 7.4.5 CCBIO Recent Developments
  25. 7.5 CSL
  26. 7.5.1 CSL Company Information
  27. 7.5.2 CSL Business Overview
  28. 7.5.3 CSL Vaccine Revenue and Gross Margin (2021-2026)
  29. 7.5.4 CSL Vaccine Product Portfolio
  30. 7.5.5 CSL Recent Developments
  31. 7.6 CureVac
  32. 7.6.1 CureVac Company Information
  33. 7.6.2 CureVac Business Overview
  34. 7.6.3 CureVac Vaccine Revenue and Gross Margin (2021-2026)
  35. 7.6.4 CureVac Vaccine Product Portfolio
  36. 7.6.5 CureVac Recent Developments
  37. 7.7 Elanco
  38. 7.7.1 Elanco Company Information
  39. 7.7.2 Elanco Business Overview
  40. 7.7.3 Elanco Vaccine Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Elanco Vaccine Product Portfolio
  42. 7.7.5 Elanco Recent Developments
  43. 7.8 GSK
  44. 7.8.1 GSK Company Information
  45. 7.8.2 GSK Business Overview
  46. 7.8.3 GSK Vaccine Revenue and Gross Margin (2021-2026)
  47. 7.8.4 GSK Vaccine Product Portfolio
  48. 7.8.5 GSK Recent Developments
  49. 7.9 Hulan Bio
  50. 7.9.1 Hulan Bio Company Information
  51. 7.9.2 Hulan Bio Business Overview
  52. 7.9.3 Hulan Bio Vaccine Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Hulan Bio Vaccine Product Portfolio
  54. 7.9.5 Hulan Bio Recent Developments
  55. 7.10 Indian Immunologicals
  56. 7.10.1 Indian Immunologicals Company Information
  57. 7.10.2 Indian Immunologicals Business Overview
  58. 7.10.3 Indian Immunologicals Vaccine Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Indian Immunologicals Vaccine Product Portfolio
  60. 7.10.5 Indian Immunologicals Recent Developments
  61. 7.11 Merck
  62. 7.11.1 Merck Company Information
  63. 7.11.2 Merck Business Overview
  64. 7.11.3 Merck Vaccine Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Merck Vaccine Product Portfolio
  66. 7.11.5 Merck Recent Developments
  67. 7.12 Minhai Biotechnology
  68. 7.12.1 Minhai Biotechnology Company Information
  69. 7.12.2 Minhai Biotechnology Business Overview
  70. 7.12.3 Minhai Biotechnology Vaccine Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Minhai Biotechnology Vaccine Product Portfolio
  72. 7.12.5 Minhai Biotechnology Recent Developments
  73. 7.13 Mitsubishi Tanabe Pharma
  74. 7.13.1 Mitsubishi Tanabe Pharma Company Information
  75. 7.13.2 Mitsubishi Tanabe Pharma Business Overview
  76. 7.13.3 Mitsubishi Tanabe Pharma Vaccine Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Mitsubishi Tanabe Pharma Vaccine Product Portfolio
  78. 7.13.5 Mitsubishi Tanabe Pharma Recent Developments
  79. 7.14 Moderna Therapeutics
  80. 7.14.1 Moderna Therapeutics Company Information
  81. 7.14.2 Moderna Therapeutics Business Overview
  82. 7.14.3 Moderna Therapeutics Vaccine Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Moderna Therapeutics Vaccine Product Portfolio
  84. 7.14.5 Moderna Therapeutics Recent Developments
  85. 7.15 Mylan
  86. 7.15.1 Mylan Company Information
  87. 7.15.2 Mylan Business Overview
  88. 7.15.3 Mylan Vaccine Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Mylan Vaccine Product Portfolio
  90. 7.15.5 Mylan Recent Developments
  91. 7.16 Plumbline Life Sciences
  92. 7.16.1 Plumbline Life Sciences Company Information
  93. 7.16.2 Plumbline Life Sciences Business Overview
  94. 7.16.3 Plumbline Life Sciences Vaccine Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Plumbline Life Sciences Vaccine Product Portfolio
  96. 7.16.5 Plumbline Life Sciences Recent Developments
  97. 7.17 Sanofi
  98. 7.17.1 Sanofi Company Information
  99. 7.17.2 Sanofi Business Overview
  100. 7.17.3 Sanofi Vaccine Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Sanofi Vaccine Product Portfolio
  102. 7.17.5 Sanofi Recent Developments
  103. 7.18 Translate Bio
  104. 7.18.1 Translate Bio Company Information
  105. 7.18.2 Translate Bio Business Overview
  106. 7.18.3 Translate Bio Vaccine Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Translate Bio Vaccine Product Portfolio
  108. 7.18.5 Translate Bio Recent Developments
  109. 7.19 Walvax Biotechnology
  110. 7.19.1 Walvax Biotechnology Company Information
  111. 7.19.2 Walvax Biotechnology Business Overview
  112. 7.19.3 Walvax Biotechnology Vaccine Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Walvax Biotechnology Vaccine Product Portfolio
  114. 7.19.5 Walvax Biotechnology Recent Developments
  115. 7.20 Wuhan Institute of Biological Products
  116. 7.20.1 Wuhan Institute of Biological Products Company Information
  117. 7.20.2 Wuhan Institute of Biological Products Business Overview
  118. 7.20.3 Wuhan Institute of Biological Products Vaccine Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Wuhan Institute of Biological Products Vaccine Product Portfolio
  120. 7.20.5 Wuhan Institute of Biological Products Recent Developments
  121. 7.21 Zoties
  122. 7.21.1 Zoties Company Information
  123. 7.21.2 Zoties Business Overview
  124. 7.21.3 Zoties Vaccine Revenue and Gross Margin (2021-2026)
  125. 7.21.4 Zoties Vaccine Product Portfolio
  126. 7.21.5 Zoties Recent Developments
8 North America
  1. 8.1 North America Vaccine Revenue (2021-2032)
  2. 8.2 North America Vaccine Revenue by Type (2021-2032)
  3. 8.2.1 North America Vaccine Revenue by Type (2021-2026)
  4. 8.2.2 North America Vaccine Revenue by Type (2027-2032)
  5. 8.3 North America Vaccine Revenue Share by Type (2021-2032)
  6. 8.4 North America Vaccine Revenue by Application (2021-2032)
  7. 8.4.1 North America Vaccine Revenue by Application (2021-2026)
  8. 8.4.2 North America Vaccine Revenue by Application (2027-2032)
  9. 8.5 North America Vaccine Revenue Share by Application (2021-2032)
  10. 8.6 North America Vaccine Revenue by Country
  11. 8.6.1 North America Vaccine Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Vaccine Revenue by Country (2021-2026)
  13. 8.6.3 North America Vaccine Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Vaccine Revenue (2021-2032)
  2. 9.2 Europe Vaccine Revenue by Type (2021-2032)
  3. 9.2.1 Europe Vaccine Revenue by Type (2021-2026)
  4. 9.2.2 Europe Vaccine Revenue by Type (2027-2032)
  5. 9.3 Europe Vaccine Revenue Share by Type (2021-2032)
  6. 9.4 Europe Vaccine Revenue by Application (2021-2032)
  7. 9.4.1 Europe Vaccine Revenue by Application (2021-2026)
  8. 9.4.2 Europe Vaccine Revenue by Application (2027-2032)
  9. 9.5 Europe Vaccine Revenue Share by Application (2021-2032)
  10. 9.6 Europe Vaccine Revenue by Country
  11. 9.6.1 Europe Vaccine Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Vaccine Revenue by Country (2021-2026)
  13. 9.6.3 Europe Vaccine Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Vaccine Revenue (2021-2032)
  2. 10.2 China Vaccine Revenue by Type (2021-2032)
  3. 10.2.1 China Vaccine Revenue by Type (2021-2026)
  4. 10.2.2 China Vaccine Revenue by Type (2027-2032)
  5. 10.3 China Vaccine Revenue Share by Type (2021-2032)
  6. 10.4 China Vaccine Revenue by Application (2021-2032)
  7. 10.4.1 China Vaccine Revenue by Application (2021-2026)
  8. 10.4.2 China Vaccine Revenue by Application (2027-2032)
  9. 10.5 China Vaccine Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Vaccine Revenue (2021-2032)
  2. 11.2 Asia Vaccine Revenue by Type (2021-2032)
  3. 11.2.1 Asia Vaccine Revenue by Type (2021-2026)
  4. 11.2.2 Asia Vaccine Revenue by Type (2027-2032)
  5. 11.3 Asia Vaccine Revenue Share by Type (2021-2032)
  6. 11.4 Asia Vaccine Revenue by Application (2021-2032)
  7. 11.4.1 Asia Vaccine Revenue by Application (2021-2026)
  8. 11.4.2 Asia Vaccine Revenue by Application (2027-2032)
  9. 11.5 Asia Vaccine Revenue Share by Application (2021-2032)
  10. 11.6 Asia Vaccine Revenue by Country
  11. 11.6.1 Asia Vaccine Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Vaccine Revenue by Country (2021-2026)
  13. 11.6.3 Asia Vaccine Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Vaccine Revenue (2021-2032)
  2. 12.2 SAMEA Vaccine Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Vaccine Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Vaccine Revenue by Type (2027-2032)
  5. 12.3 SAMEA Vaccine Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Vaccine Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Vaccine Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Vaccine Revenue by Application (2027-2032)
  9. 12.5 SAMEA Vaccine Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Vaccine Revenue by Country
  11. 12.6.1 SAMEA Vaccine Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Vaccine Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Vaccine Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst